How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,087 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Targeted Enteral Nutrient Delivery: A Prospective Randomized Study

with spermacide (by male partner), intrauterine device, sponge, spermacide, Norplant®, Depo-Provera® or oral contraceptives. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03064347 Locations Layout table for location information United States, California USC

2017 Clinical Trials

162. Adrenergic System in Islet Transplantation

daily, or an equivalent physiologic dose of hydrocortisone. For female participants of child-bearing potential: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of study participation. Oral contraceptives, intra-uterine devices, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. Treatment with any anti-diabetic medication other than (...) contraceptive measures for the duration of study participation. Oral contraceptives, intra-uterine devices, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment. Use of any investigational agents within 4 weeks of enrollment. Any medical condition that, in the opinion of the PI, will interfere with the safe completion of the study

2017 Clinical Trials

163. Exercise Physiology Study

and HIPAA documents. Exclusion Criteria: Female of childbearing potential who is pregnant, intending to become pregnant, breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill/patch/vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Any cardiovascular disease, defined as clinically significant EKG abnormality at the time of screening

2017 Clinical Trials

164. A Clinical Trial to Evaluate the Effectiveness of Hairfinity on Improving Hair Health and Rate of Growth

patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Intrauterine devices Vasectomy of partner Double Barrier Method Non-heterosexual lifestyle Fitzpatrick skin type of I-V (See appendix 3) Willing to maintain the colour of and style of the hair cut for the duration of the study Willing to maintain shampooing frequency and general hair regime for the duration of the study Willing to not cut hair

2017 Clinical Trials

165. Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)

are receiving an elemental diet or parenteral nutrition. Subjects who are treated with insulin. Women with childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or Depo-provera contraceptive, or barrier plus spermicide); pregnant or breastfeeding mothers. Subjects who will be unavailable for the duration of the trial, who are unlikely to be compliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason. Known sensitivity

2017 Clinical Trials

166. A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients

by a qualified clinician for at least 1 monthly cycle prior to study drug administration. Medroxyprogesterone acetate (eg, Depo-Provera®) administered for a minimum of 1 monthly cycle prior to administration of the study drug and continuing through 1 month following study completion. Hysterectomy or surgical sterilization. Abstinence. Double barrier method (diaphragm with spermicidal gel or condoms with contraceptive foam). NOTE: For subjects prescribed Orkambi: Orkambi may substantially decrease hormonal

2017 Clinical Trials

167. A Study Evaluating Good Idea on Glucose Homeostasis in a Healthy Population

contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) Vasectomy of partner (shown successful as per appropriate follow-up) White North American (should include Hispanic, non-Hispanic, Aboriginal and Asian) or African American Stable body weight defined as no more than ± 3 kg change during the last 2 months Agree to maintain consistent

2017 Clinical Trials

168. Targeted Microbiome Transplant in Atopic Dermatitis

pounds [95.5 Kg]); and Females of childbearing potential who are willing to use adequate contraception 30 days prior to the Screening Visit and until participation in the study is complete. --Females of childbearing potential must agree to use an acceptable method of birth control (e.g. total abstinence, oral contraceptives, intrauterine device (IUD), barrier method with spermicide, surgical sterilization or surgically sterilized partner, Depo-Provera, Norplant, NuvaRing, or hormonal implants

2017 Clinical Trials

169. Cognition and Smoking Relapse (HCS)

consent to use a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain from sexual intercourse during the time they are in the study and using transdermal nicotine. Able to communicate fluently in English. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent/HIPAA form. Exclusion Criteria: Smoking Behavior

2017 Clinical Trials

170. NMDA Receptor Modulation for Hyperarousal in PTSD

includes: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective IUD/IUS, Depo-Provera injections, oral contraceptive, and Evra Patch or Nuvaring. Women should be on a stable method of birth control for a minimum of 3 months , prior to randomization and 3 months after the last dose of IP. Women of non-childbearing potential. Women of non-childbearing potential are defined as women who are either permanently sterilized (hysterectomy

2017 Clinical Trials

171. Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

barrier method and an acceptable hormonal method must be used. Acceptable barrier methods include condom (male or female) and a spermicide (cream, film, foam, or gel), diaphragm or cervical cap with spermicide, and the birth control sponge. Acceptable hormonal methods include birth control patch, shot (Depo-Provera), and pills, and the vaginal ring (NuvaRing). **Study vaccination or CHMI Women of childbearing potential must agree to continue use of a highly effective form of contraception through 90

2017 Clinical Trials

172. PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

at screening Must be in general good health in the opinion of the investigator Regular menstrual cycles of approximately 21 to 35 days apart with no untreated intermenstrual menstrual bleeding Note: This criterion is not applicable to participants using continuous combination oral contraceptive pills or progestin-only methods (such as Depo-Provera or levonorgestrel-releasing IUD), as the absence of regular menstrual cycles is an expected, normal consequence in this context. Satisfactory cervical Pap result

2017 Clinical Trials

173. Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

<50,000; Blood donation (1 pint of whole blood) within the past 2 months; Active alcohol abuse or substance abuse; Current administration of oral or parenteral corticosteroids; Pregnancy and/ or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera

2017 Clinical Trials

174. Carbohydrate Availability and microRNA Expression

aerobic and/or resistance exercise Refrain from taking any NSAIDS (i.e., aspirin, Advil®, Aleve®, Naprosyn®, or any aspirin-containing product for 10 days before and at least 5 days AFTER each muscle biopsy. (*Tylenol® or acetaminophen is ok to use if needed for discomfort) Refrain from the use of alcohol and nicotine for the duration of the study Females must be on contraception (e.g., oral birth control, NuvaRing®, Depo Provera®, etc.) Supervisor approved leave status for federal civilian employees

2017 Clinical Trials

175. Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide

control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence. Exclusion Criteria: Male subjects. Post-menopausal women. Women who do not suffer from acne. Subjects who are allergic to clindamycin, benzoyl peroxide, lidocaine or any other ingredients listed in the study medication. Subjects with an unstable medical condition

2017 Clinical Trials

176. Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women

: October 31, 2018 See Sponsor: Johns Hopkins University Collaborator: University of Maryland Information provided by (Responsible Party): Johns Hopkins University Study Details Study Description Go to Brief Summary: The investigators are doing a study on the bacteria that normally live in the vagina and what effect, if any, Depo-Provera has on the bacteria. Women 13-24 years of age, who are HIV negative, being seen in a clinic for birth control or sexually transmitted disease (STD) check-up, or have (...) a child and are planning to receive a Depo-Provera shot for contraception or have declined the use of hormonal contraception may join. Condition or disease Intervention/treatment Microbial Colonization Other: No intervention Detailed Description: The investigators are doing a study on the bacteria that normally live in the vagina and what effect, if any, Depo-Provera has on the bacteria. Women 13-24 years of age, who are HIV negative, being seen in a clinic for birth control or STD check-up, or have

2017 Clinical Trials

177. Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder

sterilization oral contraceptives (consisting of an estrogen-progestin combination or progestin alone transdermally derived contraceptives (e.g., Ortho - Evra), depot injections (e.g., Depo-Provera) vagina contraceptive ring (e.g., Nucaring), contraceptive implants (e.g., Implanon, Norplant 2/Jadelle) an intrauterine device diaphragm plus condom (the only acceptable double barrier method) other forms of contraceptives (pharmacological and/or non-pharmacological) are not accepted Subject has had concomitant

2017 Clinical Trials

178. Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes

. Pregnancy and/ or Lactation: Women of childbearing potential will be required to have a negative urine pregnancy test and to use contraception measures during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Moderate anemia, defined as hemoglobin <10.9 in both men

2017 Clinical Trials

179. 18F-FET PET in Childhood Brain Tumours

IntraUterineDevice (IUD), Mirena IUD, Implants, Depo Provera Injections; Persons who are detained officially or legally to an official institute Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03216148 Contacts Layout table for location contacts Contact: Uwe

2017 Clinical Trials

180. Directed Ablation of Uterine Fibroids Using a Noninvasive Approach

intracavitary) Patients with known endometrial hyperplasia. Patients planning or seeking additional therapies for the treatment of fibroids and/or abnormal uterine bleeding. Patients with other pelvic masses of unknown etiology. Patients who are postmenopausal. Patients with an active diagnosis of cancer of any type. Patients on hormone therapy such as Depo-Provera, Lupron, etc. Patients who within 6 months prior to enrollment had procedures or surgery for the fibroid(s) to be treated as part

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>